Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno, Masao Tanaka(Kyushu University), Shinichi Egawa(Tohoku University), Narikazu Boku(Tokyo National Hospital), Ann‐Lii Cheng(National Taiwan University), Masafumi Ikeda(National Cancer Center Hospital East), Tatsuya Ioka(National Cancer Center Hospital East), Hiroaki Yanagimoto(National Cancer Center Hospital East), Masayuki Sho(Nara Medical University), T Shimamura(National Cancer Center Hospital East), Jen‐Shi Chen(Chang Gung University), Junji Furuse(Kyorin University), Kazuhiro Mizumoto(National Cancer Center Hospital East), Masayuki Kitano(National Cancer Center Hospital East), Taketo Yamaguchi(National Cancer Center Hospital East), Takuji Okusaka(National Cancer Center), Kenji Yamao(National Cancer Center Hospital East), Yasuo Ohashi(National Cancer Center Hospital East), Hideo Baba(Kumamoto University), Atsushi Satō(National Cancer Center Hospital East), Takashi Hatori(National Cancer Center Hospital East), Shinichi Ohkawa(National Cancer Center Hospital East), Kazuya Sugimori(National Cancer Center Hospital East), Akihiro Funakoshi(National Cancer Center Hospital East), Akira Fukutomi(Shizuoka Cancer Center)
Cited by 632
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k